Biology of Blood and Marrow Transplantation
Volume 12, Issue 1 , Pages 84-94 , January 2006

Extended Lamivudine Therapy against Hepatitis B Virus Infection in Hematopoietic Stem Cell Transplant Recipients

  • Liang-Tsai Hsiao

      Affiliations

    • Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
    • National Yang-Ming University School of Medicine, Taipei, Taiwan
    • ,
  • Tzeon-Jye Chiou

      Affiliations

    • Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
    • National Yang-Ming University School of Medicine, Taipei, Taiwan
    • ,
  • Jin-Hwang Liu

      Affiliations

    • Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
    • National Yang-Ming University School of Medicine, Taipei, Taiwan
    • ,
  • Chiau-Jun Chu

      Affiliations

    • Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
    • National Yang-Ming University School of Medicine, Taipei, Taiwan
    • ,
  • Yu-Chen Lin

      Affiliations

    • Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
    • National Yang-Ming University School of Medicine, Taipei, Taiwan
    • ,
  • Ta-Chung Chao

      Affiliations

    • Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
    • National Yang-Ming University School of Medicine, Taipei, Taiwan
    • ,
  • Wei-Shu Wang

      Affiliations

    • Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
    • National Yang-Ming University School of Medicine, Taipei, Taiwan
    • ,
  • Chueh-Chuan Yen

      Affiliations

    • Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
    • National Yang-Ming University School of Medicine, Taipei, Taiwan
    • ,
  • Muh-Hwa Yang

      Affiliations

    • Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
    • National Yang-Ming University School of Medicine, Taipei, Taiwan
    • ,
  • Cheng-Hwai Tzeng

      Affiliations

    • National Yang-Ming University School of Medicine, Taipei, Taiwan
    • Division of Transfusion Medicine, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
    • ,
  • Po-Min Chen

      Affiliations

    • Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
    • National Yang-Ming University School of Medicine, Taipei, Taiwan
    • Corresponding Author InformationCorrespondence and reprint requests: Po-Min Chen, MD, PhD, Division of Medical Oncology, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Rd., Taipei 11217, Taiwan.

Received 14 July 2005 ,Accepted 2 September 2005.

References 

  1. Clark FL , Drummond MW , Chambers S , Chapman BA , Patton WN . Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin’s lymphoma . Ann Oncol . 1998;9:385–387
  2. Yeo W , Steinberg JL , Tam JS , et al.   Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy . J Med Virol . 1999;59:263–269
  3. Liao CA , Lee CM , Wu HC , Wang MC , Lu SN , Eng HL . Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin’s lymphoma . Br J Haematol . 2002;116:166–169
  4. Picardi M , Selleri C , De Rosa G , Raiola A , Pezzullo L , Rotoli B . Lamivudine treatment for chronic replicative hepatitis B virus infection after allogeneic bone marrow transplantation . Bone Marrow Transplant . 1998;21:1267–1269
  5. Hashino S , Nozawa A , Izumiyama K , et al.   Lamivudine treatment for reverse seroconversion of hepatitis B 4 years after allogeneic bone marrow transplantation . Bone Marrow Transplant . 2002;29:361–363
  6. Nakagawa M , Simizu Y , Suemura M , Sato B . Successful long-term control with lamivudine against reactivated hepatitis B infection following intensive chemotherapy and autologous peripheral blood stem cell transplantation in non-Hodgkin’s lymphoma (experience of 2 cases) . Am J Hematol . 2002;70:60–63
  7. Henkes M , Martin S , Einsele H , Aulitzky WE . Successful antiviral treatment for fulminant reactivated hepatitis B after autologous stem cell transplantation and prophylaxis during subsequent allogeneic stem cell transplantation . Ann Hematol . 2002;81:343–346
  8. Al Taie OH , Mork H , Gassel AM , Wilhelm M , Weissbrich B , Scheurlen M . Prevention of hepatitis B flare-up during chemotherapy using lamivudine (case report and review of the literature) . Ann Hematol . 1999;78:247–249
  9. Silvestri F , Sperotto A , Ermacora A , Fanin R , Damiani D , Baccarani M . Lamivudine for the prevention of hepatitis B virus reactivation during autologous stem cell transplantation. A case report . Haematologica . 2000;85:327–329
  10. Silvestri F , Ermacora A , Sperotto A , et al.   Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation . Br J Haematol . 2000;108:394–396
  11. Uchida N , Gondo H , Himeji D , Kaji Y , Sata M , Niho Y . Lamivudine therapy for a hepatitis B surface antigen (HBsAg)-positive leukemia patient receiving myeloablative chemotherapy and autologous stem cell transplantation . Bone Marrow Transplant . 2000;26:1243–1245
  12. Endo T , Sakai T , Fujimoto K , et al.   A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin’s lymphoma . Bone Marrow Transplant . 2001;27:433–436
  13. Rossi G , Pelizzari A , Motta M , Puoti M . Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy . Br J Haematol . 2001;115:58–62
  14. Persico M , De Marino F , Russo GD , et al.   Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma . Blood . 2002;99:724–725
  15. Shibolet O , Ilan Y , Gillis S , Hubert A , Shouval D , Safadi R . Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers . Blood . 2002;100:391–396
  16. Ohnishi M , Kanda Y , Takeuchi T , et al.   Limited efficacy of lamivudine against hepatitis B virus infection in allogeneic hematopoietic stem cell transplant recipients . Transplantation . 2002;73:812–815
  17. Lau GK , He ML , Fong DY , et al.   Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation . Hepatology . 2002;36:702–709
  18. Chen DS , Sung JL . Hepatitis B virus infection and chronic liver disease in Taiwan . Acta Hepatogastroenterol (Stuttg) . 1978;25:423–430
  19. Chen PM , Fan S , Liu CJ , et al.   Changing of hepatitis B virus markers in patients with bone marrow transplantation . Transplantation . 1990;49:708–713
  20. Chen PM , Liu JH , Fan FS , et al.   Liver disease after bone marrow transplantation—the Taiwan experience . Transplantation . 1995;59:1139–1143
  21. Chen PM , Chiou TJ , Fan FS , et al.   Fulminant hepatitis is significantly increased in hepatitis B carriers after allogeneic bone marrow transplantation . Transplantation . 1999;67:1425–1433
  22. Chen PM , Yao NS , Wu CM , et al.   Detection of reactivation and genetic mutations of the hepatitis B virus in patients with chronic hepatitis B infections receiving hematopoietic stem cell transplantation . Transplantation . 2002;74:182–188
  23. Paraskevis D , Haida C , Tassopoulos N , et al.   Development and assessment of a novel real-time PCR assay for quantitation of HBV DNA . J Virol Methods . 2002;103:201–212
  24. Pawlotsky JM . Molecular diagnosis of viral hepatitis . Gastroenterology . 2002;122:1554–1568
  25. Naito H , Hayashi S , Abe K . Rapid and specific genotyping system for hepatitis B virus corresponding to six major genotypes by PCR using type-specific primers . J Clin Microbiol . 2001;39:362–364
  26. Lok AS , Heathcote EJ , Hoofnagle JH . Management of hepatitis B (2000—summary of a workshop) . Gastroenterology . 2001;120:1828–1853
  27. Chan HL , Hussain M , Lok AS . Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion . Hepatology . 1999;29:976–984
  28. Stuyver LJ , Locarnini SA , Lok A , et al.   Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region . Hepatology . 2001;33:751–757
  29. Chayama K , Suzuki Y , Kobayashi M , et al.   Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy . Hepatology . 1998;27:1711–1716
  30. McDonald GB , Sharma P , Matthews DE , Shulman HM , Thomas ED . Venocclusive disease of the liver after bone marrow transplantation (diagnosis, incidence, and predisposing factors) . Hepatology . 1984;4:116–122
  31. Glucksberg H , Storb R , Fefer A , et al.   Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors . Transplantation . 1974;18:295–304
  32. Shulman HM , Sullivan KM , Weiden PL , et al.   Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients . Am J Med . 1980;69:204–217
  33. Lai CL , Chien RN , Leung NW , et al.  Asia Hepatitis Lamivudine Study Group   A one-year trial of lamivudine for chronic hepatitis B . N Engl J Med . 1998;339:61–68
  34. Hadziyannis SJ , Papatheodoridis GV , Dimou E , Laras A , Papaioannou C . Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B . Hepatology . 2000;32:847–851
  35. Kosaka Y , Takase K , Kojima M , et al.   Fulminant hepatitis B (induction by hepatitis B virus mutants defective in the precore region and incapable of encoding e antigen) . Gastroenterology . 1991;100:1087–1094
  36. Miura Y , Takamatsu H , Okumura H , Yoshida T , Nakao S , Matsuda T . Allogeneic bone marrow transplantation for a patient complicated by chronic hepatitis due to precore mutant hepatitis B virus (failure of management with interferon-alpha therapy) . Am J Hematol . 1997;54:344–345
  37. Lau GK , Leung YH , Fong DY , et al.   High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation . Blood . 2002;99:2324–2330
  38. Lin HH , Kao JH , Chang TC , Hsu HY , Chen DS . Secular trend of age-specific prevalence of hepatitis B surface and e antigenemia in pregnant women in Taiwan . J Med Virol . 2003;69:466–470
  39. Chan HL , Leung NW , Hussain M , Wong ML , Lok AS . Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong . Hepatology . 2000;31:763–768
  40. Hadziyannis SJ , Vassilopoulos D . Hepatitis B e antigen-negative chronic hepatitis B . Hepatology . 2001;34:617–624
  41. Kobayashi S , Ide T , Sata M . Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers . J Hepatol . 2001;34:584–586
  42. Kirishima T , Okanoue T , Daimon Y , et al.   Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment . J Hepatol . 2002;37:259–265
  43. Besisik F , Karaca C , Akyuz F , et al.   Occult HBV infection and YMDD variants in hemodialysis patients with chronic HCV infection . J Hepatol . 2003;38:506–510
  44. Bowden S , Bartholomeusz A , Locarnini S . Lamivudine resistant occult HBV (implications for public health?) . J Hepatol . 2003;38:526–528
  45. Liu CJ , Chen PJ , Lai MY , Kao JH , Chen DS . Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences . Hepatology . 2001;34:583–589
  46. Papatheodoridis GV , Dimou E , Laras A , Papadimitropoulos V , Hadziyannis SJ . Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease . Hepatology . 2002;36:219–226
  47. Myers RP , Swain MG , Urbanski SJ , Lee SS . Reactivation of hepatitis B e antigen-negative chronic hepatitis B in a bone marrow transplant recipient following lamivudine withdrawal . Can J Gastroenterol . 2001;15:599–603
  48. Cainelli F , Longhi MS , Concia E , Vento S . Failure of lamivudine therapy for chemotherapy-induced reactivation of hepatitis B . Am J Gastroenterol . 2001;96:1651–1652
  49. Petrelli E , Balducci M , Pieretti C , Rocchi MB , Clementi M , Manzin A . Lamivudine treatment failure in preventing fatal outcome of de novo severe acute hepatitis B in patients with haematological diseases . J Hepatol . 2001;35:823–826
  50. Kojima H , Abei M , Takei N , et al.   Fatal reactivation of hepatitis B virus following cytotoxic chemotherapy for acute myelogenous leukemia (fibrosing cholestatic hepatitis) . Eur J Haematol . 2002;69:101–104
  51. Simpson ND , Simpson PW , Ahmed AM , et al.   Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with lamivudine . J Clin Gastroenterol . 2003;37:68–71

PII: S1083-8791(05)00629-4

doi: 10.1016/j.bbmt.2005.09.001

Biology of Blood and Marrow Transplantation
Volume 12, Issue 1 , Pages 84-94 , January 2006

Article Tools

* Image Usage & Resolution